ClinicalTrials.gg
RecruitingNCT07532655Updated Oct 23, 2026

A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants

A Phase 1 interventional study of SYH2082 Injection and Placebo in Overweight or Obesity, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 23, 2026Now RecruitingFirst site in Australia+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 188 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.

Planned enrollment
121st of 169
60 · median 180
Started
2026
with 40 others
Phase 1
33 of 188
15 open now
Primary completion
2027-01
later than 11 of 73 live
Registered
165th of 188
by date

Among the 188 studies in Obesity with a site in Australia, this one is the 121st largest by planned enrollment of the 169 interventional ones that give a count, is one of 41 that started in 2026, is one of 33 in phase 1, reaches primary completion later than 11 of the 73 other live ones, and was the 165th registered.

Obesity

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

56 of the 188 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:

50 more — sign in →

All 56 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Obesity with a site in Australia, or all of them as a file.
02

Study summary

To evaluate the safety and tolerability of single dose and multiple doses of SYH2082 Injection in healthy participants.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's planned enrollment of 60 is below the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor of 167 studies on the registry; 47 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fully understands the content, procedures, and possible adverse reactions of the study, and voluntarily signs the ICF before the study;
  • At screening, age 18-65 years (inclusive, at the time of signing the ICF), male or female;
  • At screening, body weight ≥50 kg for males and ≥45 kg for females; (BMI) between 22.0 and 40.0 kg/m2 (inclusive) for SAD part, between 25.0 and 40.0 kg/m2 for MAD part;
  • Body weight change ≤5% within 3 months prior to screening (including the screening period), which shall satisfy both of the following two conditions simultaneously:

    1. Participant-recalled weights in the 3 months prior to screening are documented and used to calculate percentage weight change for the purpose of assessing the eligibility criterion (≤5%);
    2. Calibrated weights obtained at the site (e.g. Screening (D-35 to D-3 for SAD, D-35 to D-2 for MAD) and Check-in (D-2 for SAD, D-1 for MAD) visits) are compared to confirm stability between screening and check-in on the standardized, controlled scale;
  • From the time of signing the ICF until 6 months after the last dose, the participant (including their partner) has no plans for childbirth and agrees to use highly effective measures (oral hormonal contraceptives are prohibited).

Exclusion criteria

Exclusion Criteria:

  • Known or suspected allergy to glucagon-like peptide-1 (GLP-1) or Glucose dependent insulinotropic polypeptide (GIP) receptor agonists or any component of the product; or has an allergic constitution (allergic to multiple drugs and foods);
  • Abnormal results in vital signs, physical examination, laboratory tests, and that are judged by the investigator to be within the screening period. Specifically, the following conditions are not exclusionary:

    1. Systolic blood pressure (SBP) \< 160 mmHg, diastolic blood pressure (DBP) \< 100 mmHg;
    2. Fasting TG ≤ 5.6 mmol/L, fasting TC ≤ 7.5 mmol/L, fasting LDL-C ≤ 5 mmol/L, and abnormal fasting HDL-C;
    3. (ALT) \< 2 × , aspartate aminotransferase (AST) \< 2 × ULN, gamma-glutamyl transferase (GGT) \< 2.5 × ULN, and total (TBIL) \< 1.5 × ULN. Participants with values outside the normal range may be included if the abnormality is deemed benign by the investigator (e.g., Gilbert's syndrome);
  • History or laboratory evidence of diabetes mellitus (type 2, type 1, or other forms of diabetes), including fasting glucose of ≥126 mg/dL (7.0 mmol/L) and/or ≥ 6.5% within the screening period;
  • With any previous episode of hypoglycemia or with screening fasting glucose \< 3.9mmol/L (even on a single sample);
  • With obesity due to identifiable endocrinologic, genetic or syndromic causes;
  • Meets any of the following criteria within the screening period:

    1. Calcitonin ≥25 ng/L (≥ 7.31 pmol/L);
    2. Estimated (eGFR) \<80 mL/min/1.73m2
    3. Thyroid-stimulating hormone (TSH) outside the normal reference range;
    4. Fasting serum amylase and/or lipase >1.5× ULN.
  • At screening, has a prolonged /QTc interval (QTcF >450 ms for males and QTcF>470 ms for females), or a history of risk factors for Torsades de Pointes (e.g., cardiac failure/cardiomyopathy or a family history of long QT syndrome), or is currently taking concomitant medications that prolong the QT/QTc interval;
  • Positive for any of the following: surface antigen, virus antibody, antibody, or syphilis serology;
  • Significant history or clinical manifestation of any metabolic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, immune or psychiatric disorder as determined by the Investigator or medical designees;
  • History of severe trauma or major surgery within 3 months prior to screening, or plans to undergo surgery or any procedures requiring general anesthesia or sedation during the study period;
  • History of thyroid nodules diagnosed as C-TIRADS category 3 or higher;
  • Personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia syndrome type 2, or a personal history of pancreatitis or gallbladder/gallstone disease;
  • History of , except for non-melanoma skin cancer excised more than 1 year prior to Screening and cervical intraepithelial neoplasia that has been successfully cured more than 2 years prior to Screening;
  • History of major depressive disorder; any clinically significant mental health condition (in the opinion of the principal investigator) or any mental health condition requiring medication or psychological therapy in the last 2 years;
  • Lifetime history of any suicide attempts or suicide behavior according to the C-SSRS, or any suicidal ideation in the last two years according to the C-SSRS;
  • Non-suicidal self-injury more than 5 years ago is permissible, if it is clear there was no suicidal intent. Participants should be excluded if any doubt;
  • History of gastric emptying abnormalities (e.g., gastric outlet obstruction) or severe chronic gastrointestinal diseases (e.g., inflammatory bowel disease, active ulcer);
  • History of gastrointestinal surgery that could lead to malabsorption, or long-term use of drugs that directly affect gastrointestinal motility. This includes any lifetime history of bariatric surgery or procedures (e.g., gastric banding), regardless of when they were performed;
  • History of use GLP-1 or GIP receptor agonists or any drug or product that may cause weight changes and affect weight assessment considered by the investigator within 3 months prior to screening;
  • Has dermatitis or other skin abnormalities (including tattoos) at or around the injection site;
  • Use of any prescription drugs within 2 weeks prior to dosing or no more than 5 half-lives (whichever is longer) after the last use of the above drugs. Non-prescription drugs, herbal preparations and supplements excluded 7 days prior to dosing, and allow short term use of paracetamol and anti-inflammatory drug use within the 7 days prior to dosing, within investigator discretion. Vaccination restrictions are differentiated by vaccine type and apply from 14 days prior to the first study drug dose through 29 days after the last study drug dose:

    1. Inactivated vaccines: prohibited within 14 days prior to dosing;
    2. : prohibited within 28 days prior to dosing; All vaccinations are prohibited from dosing through 29 days post-dosing;
  • Use of drugs that may affect glucose metabolism (e.g., systemic , non-selective β-blockers, monoamine oxidase inhibitors) within 1 month prior to screening, or no more than 5 half-lives (whichever is longer) after the last use of the above drugs;
  • Average weekly alcohol consumption exceeding 21 units (males) / 14 units (females) within 3 months prior to screening (1 unit ≈ 375 mL of mid-strength beer (3.5% alcohol/volume), 100 mL of wine (13.5% alcohol/volume), or 30 mL of spirits (40% alcohol/volume)), or has a positive alcohol breath test, or is unable to abstain from alcohol during the hospital stay;
  • Smokes more than 10 cigarettes per day on average within 3 months prior to screening, or is unable to stop using any nicotine products during the hospital stay;
  • Consumes excessive amounts of tea, coffee, and/or caffeinated beverages (average of more than 8 cups per day, 1 cup ≈ 250 mL) within 3 months prior to screening, or is unable to stop consumption during the hospital stay;
  • Engaged in strenuous exercise within 48 hours prior to clinic visits, such as weightlifting, sprinting, long-distance running, cycling, swimming, or playing football;
  • History of drug abuse within 6 months prior to screening, or a positive drug abuse screening test at screening and D-2/D-1;
  • Has donated blood or plasma within 30 days prior to screening or had a loss of whole blood of more than 500ml within the 30 days prior to screening, or receipt of a blood transfusion within one year prior to screening;
  • History of needle or blood phobia, difficulty with blood collection, or unable to tolerate intravenous blood draws;
  • Has special dietary requirements and cannot adhere to the standardized diet and schedule;
  • Female participants who are pregnant, lactating, or have a positive pregnancy test result at screening and D-2/D-1;
  • Has received an investigational agent/device in another clinical study within 3 months or 5 half-lives prior to Screening (whichever is longer), or is currently participating in or plans to participate in another drug or medical device clinical study during the study period;
  • Participants whom the investigator considers to have other factors making them unsuitable for participation in this trial.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    SYH2082 Injection

    Single-ascending dose and multiple-dose doses

    Drug: SYH2082 Injection

  • Placebo comparator
    Placebo

    Conduct in accordance with the study protocol.

    Drug: Placebo

Interventions

  • DrugSYH2082 Injection

    Conduct in accordance with the study protocol.

  • DrugPlacebo

    A subcutaneous injection in the abdomen of the corresponding dose of Placebo according to the assigned dose cohort.

07

What researchers measure

Primary outcomes

  1. Number of Adverse Events as a measure of safety and tolerability of SYH2082

    Time frame: SAD: Screening period up to day 57 MAD: Screening period up to day 85

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85

  2. Area under the concentration-time curve from time 0 to the last measurable time point (AUClast)

    Time frame: SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85

  3. Area under the concentration time curve from time 0 to infinity (AUCinf)

    Time frame: SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85

  4. Time to maximum concentration (Tmax)

    Time frame: SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85

  5. Elimination half-life (t1/2)

    Time frame: SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85

  6. Apparent volume of distribution (Vz/F)

    Time frame: SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85

  7. Apparent clearance (CL/F)

    Time frame: SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85

  8. Anti-SYH2082 antibodies

    Time frame: SAD: Pre-dose at day 1 to day 57. MAD: Pre-dose at day 1 to day 85

  9. Change in fasting plasma glucose from baseline

    Time frame: SAD: Baseline up to Day 57

  10. Change in fasting insulin from baseline

    Time frame: SAD: Baseline up to Day 57 MAD: Baseline up to Day 85

  11. Change in C-peptide from baseline

    Time frame: SAD: Baseline up to Day 57 MAD: Baseline up to Day 85

  12. Change in glucagon from baseline

    Time frame: SAD: Baseline up to Day 57

  13. Change in body weight from baseline

    Time frame: SAD: Baseline up to Day 57 MAD: Baseline up to Day 85

  14. Change in waist circumference from baseline

    Time frame: SAD: Baseline up to Day 57 MAD: Baseline up to Day 85

  15. Corrected QT(QTc) interval

    Baseline- and placebo-corrected QTcF (ΔΔQTcF)

    Time frame: SAD: Pre-dose at day 1 to day 8 MAD: Pre-dose at day-1 to day 36

08

Study locations

1 of 1 sites recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 9 months after the start.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 9 months is close to that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Oct 2026 → Jan 2027 and completion Feb 2027 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 16, 2026
StartActual
Apr 10, 2026
Primary completionEst.
Jan 30, 2027was Oct 2026
CompletionEst.
May 9, 2027was Feb 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 23, 2026
Sites
1 site added — first site in Australia
Show site
  • Linear Clinical Research · Nedlands, Australia
Oct 23, 2026
Start date
Apr 14, 2026→Apr 10, 2026 (actual)
Oct 23, 2026
Primary completion
Oct 28, 2026→Jan 30, 2027
Oct 23, 2026
Study completion
Feb 9, 2027→May 9, 2027
Oct 23, 2026
Enrollment
44→60
Oct 23, 2026
Eligibility
3 inclusion criteria edited, 2 added; 8 exclusion criteria edited, 2 added
What changed in the criteria
Inclusion criteria
  • EditedAt screening, body weight ≥50 kg for males and ≥45 kg for females; body mass index (BMI) between 22.0 and 40.0 kg/m2 (inclusive) for SAD part, between 25.0 and 40.0 kg/m2 for MAD part;
  • EditedBody weight change ≤5% within 3 months prior to screening (including the screening period);, which shall satisfy both of the following two conditions simultaneously:
  • AddedParticipant-recalled weights in the 3 months prior to screening are documented and used to calculate percentage weight change for the purpose of assessing the eligibility criterion (≤5%);
  • AddedCalibrated weights obtained at the site (e.g. Screening (D-35 to D-3 for SAD, D-35 to D-2 for MAD) and Check-in (D-2 for SAD, D-1 for MAD) visits) are compared to confirm stability between screening and check-in on the standardized, controlled scale;
  • EditedFrom the time of signing the ICF until 6 months after the last dose, the participant (including their partner) has no plans for childbirth and agrees to use highly effective contraceptive measures (oral hormonal contraceptives are prohibited).
Exclusion criteria
  • EditedAbnormal results in vital signs, physical examination, laboratory tests, and ECG that are judged by the investigator to be clinically significant within the screening period. Specifically, the following conditions are not excludedexclusionary:
  • EditedCalcitonin ≥25 ng/L (≥ 7.31 pmol/L);
  • ChangedBefore History of major depressive disorder, including any medication or psychological therapy, in the last 2 years, or any clinically significant mental health condition;Now History of major depressive disorder; any clinically significant mental health condition (in the opinion of the principal investigator) or any mental health condition requiring medication or psychological therapy in the last 2 years;
  • EditedHistory of gastrointestinal surgery that could lead to malabsorption, or long-term use of drugs that directly affect gastrointestinal motility. For example: has undergoneThis includes any lifetime history of bariatric surgery or procedures (e.g., gastric banding) within 3 months prior to screening, regardless of when they were performed;
  • EditedUse of any prescription drugs, within 2 weeks prior to dosing or no more than 5 half-lifelives (whichever is longer) after the last use of the above drugs. Non-prescription drugs, herbal preparations and supplements excluded 7 days prior to dosing, and allow short term use of paracetamol and anti-inflammatory drug use within the 7 days prior to dosing, within investigator discretion;. Vaccination restrictions are differentiated by vaccine type and apply from 14 days prior to the first study drug dose through 29 days after the last study drug dose:
  • AddedInactivated vaccines: prohibited within 14 days prior to dosing;
  • AddedLive attenuated vaccines: prohibited within 28 days prior to dosing; All vaccinations are prohibited from dosing through 29 days post-dosing;
  • EditedUse of drugs that may affect glucose metabolism (e.g., systemic steroids, non-selective β-blockers, monoamine oxidase inhibitors) within 1 month prior to screening, or no more than 5 half-lifelives (whichever is longer) after the last use of the above drugs;
  • EditedHistory of drug abuse within 6 months prior to screening, or a positive drug abuse screening test at screening and D-2/D-1;
  • EditedFemale participants who are pregnant, lactating, or have a positive pregnancy test result at screening and D-2/D-1;
Oct 23, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameNumber of Adverse Events as a measure of safety and tolerability of SYH2082Screening period up to day 57 → SAD: Screening period up to day 57 MAD: Screening period up to day 85
Oct 23, 2026
Secondary outcomes
15 time frame changed
What changed in the outcomes
  • Time frameMaximum plasma concentration (Cmax)Pre-dose at day 1 to day 57 → SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85
  • Time frameArea under the concentration-time curve from time 0 to the last measurable time point (AUClast)Pre-dose at day 1 to day 57 → SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85
  • Time frameArea under the concentration time curve from time 0 to infinity (AUCinf)Pre-dose at day 1 to day 57 → SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85
  • Time frameTime to maximum concentration (Tmax)Pre-dose at day 1 to day 57 → SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85
  • Time frameElimination half-life (t1/2)Pre-dose at day 1 to day 57 → SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85
  • Time frameApparent volume of distribution (Vz/F)Pre-dose at day 1 to day 57 → SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85
  • Time frameApparent clearance (CL/F)Pre-dose at day 1 to day 57 → SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85
  • Time frameAnti-SYH2082 antibodiesPre-dose at day 1 to day 57 → SAD: Pre-dose at day 1 to day 57. MAD: Pre-dose at day 1 to day 85
  • Time frameChange in fasting plasma glucose from baselineBaseline up to Day 57 → SAD: Baseline up to Day 57
  • Time frameChange in fasting insulin from baselineBaseline up to Day 57 → SAD: Baseline up to Day 57 MAD: Baseline up to Day 85
  • Time frameChange in C-peptide from baselineBaseline up to Day 57 → SAD: Baseline up to Day 57 MAD: Baseline up to Day 85
  • Time frameChange in glucagon from baselineBaseline up to Day 57 → SAD: Baseline up to Day 57
  • Time frameChange in body weight from baselineBaseline up to Day 57 → SAD: Baseline up to Day 57 MAD: Baseline up to Day 85
  • Time frameChange in waist circumference from baselineBaseline up to Day 57 → SAD: Baseline up to Day 57 MAD: Baseline up to Day 85
  • Time frameCorrected QT(QTc) intervalPre-dose at day 1 to day 8 → SAD: Pre-dose at day 1 to day 8 MAD: Pre-dose at day-1 to day 36
Oct 23, 2026
Title
A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Australia
    Show site
    • Linear Clinical Research · Nedlands, Australia
    Start date Apr 14, 2026→Apr 10, 2026 (now actual)
    Primary completion Oct 28, 2026→Jan 30, 2027
    Study completion Feb 9, 2027→May 9, 2027
    Enrollment 44→60
    Eligibility 3 inclusion criteria edited, 2 added; 8 exclusion criteria edited, 2 added
    What changed in the criteria
    Inclusion criteria
    • EditedAt screening, body weight ≥50 kg for males and ≥45 kg for females; body mass index (BMI) between 22.0 and 40.0 kg/m2 (inclusive) for SAD part, between 25.0 and 40.0 kg/m2 for MAD part;
    • EditedBody weight change ≤5% within 3 months prior to screening (including the screening period);, which shall satisfy both of the following two conditions simultaneously:
    • AddedParticipant-recalled weights in the 3 months prior to screening are documented and used to calculate percentage weight change for the purpose of assessing the eligibility criterion (≤5%);
    • AddedCalibrated weights obtained at the site (e.g. Screening (D-35 to D-3 for SAD, D-35 to D-2 for MAD) and Check-in (D-2 for SAD, D-1 for MAD) visits) are compared to confirm stability between screening and check-in on the standardized, controlled scale;
    • EditedFrom the time of signing the ICF until 6 months after the last dose, the participant (including their partner) has no plans for childbirth and agrees to use highly effective contraceptive measures (oral hormonal contraceptives are prohibited).
    Exclusion criteria
    • EditedAbnormal results in vital signs, physical examination, laboratory tests, and ECG that are judged by the investigator to be clinically significant within the screening period. Specifically, the following conditions are not excludedexclusionary:
    • EditedCalcitonin ≥25 ng/L (≥ 7.31 pmol/L);
    • ChangedBefore History of major depressive disorder, including any medication or psychological therapy, in the last 2 years, or any clinically significant mental health condition;Now History of major depressive disorder; any clinically significant mental health condition (in the opinion of the principal investigator) or any mental health condition requiring medication or psychological therapy in the last 2 years;
    • EditedHistory of gastrointestinal surgery that could lead to malabsorption, or long-term use of drugs that directly affect gastrointestinal motility. For example: has undergoneThis includes any lifetime history of bariatric surgery or procedures (e.g., gastric banding) within 3 months prior to screening, regardless of when they were performed;
    • EditedUse of any prescription drugs, within 2 weeks prior to dosing or no more than 5 half-lifelives (whichever is longer) after the last use of the above drugs. Non-prescription drugs, herbal preparations and supplements excluded 7 days prior to dosing, and allow short term use of paracetamol and anti-inflammatory drug use within the 7 days prior to dosing, within investigator discretion;. Vaccination restrictions are differentiated by vaccine type and apply from 14 days prior to the first study drug dose through 29 days after the last study drug dose:
    • AddedInactivated vaccines: prohibited within 14 days prior to dosing;
    • AddedLive attenuated vaccines: prohibited within 28 days prior to dosing; All vaccinations are prohibited from dosing through 29 days post-dosing;
    • EditedUse of drugs that may affect glucose metabolism (e.g., systemic steroids, non-selective β-blockers, monoamine oxidase inhibitors) within 1 month prior to screening, or no more than 5 half-lifelives (whichever is longer) after the last use of the above drugs;
    • EditedHistory of drug abuse within 6 months prior to screening, or a positive drug abuse screening test at screening and D-2/D-1;
    • EditedFemale participants who are pregnant, lactating, or have a positive pregnancy test result at screening and D-2/D-1;
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameNumber of Adverse Events as a measure of safety and tolerability of SYH2082Screening period up to day 57 → SAD: Screening period up to day 57 MAD: Screening period up to day 85
    Secondary outcomes 15 time frame changed
    What changed in the outcomes
    • Time frameMaximum plasma concentration (Cmax)Pre-dose at day 1 to day 57 → SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85
    • Time frameArea under the concentration-time curve from time 0 to the last measurable time point (AUClast)Pre-dose at day 1 to day 57 → SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85
    • Time frameArea under the concentration time curve from time 0 to infinity (AUCinf)Pre-dose at day 1 to day 57 → SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85
    • Time frameTime to maximum concentration (Tmax)Pre-dose at day 1 to day 57 → SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85
    • Time frameElimination half-life (t1/2)Pre-dose at day 1 to day 57 → SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85
    • Time frameApparent volume of distribution (Vz/F)Pre-dose at day 1 to day 57 → SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85
    • Time frameApparent clearance (CL/F)Pre-dose at day 1 to day 57 → SAD: Pre-dose at day 1 to day 57 MAD: Pre-dose at day 1 to day 85
    • Time frameAnti-SYH2082 antibodiesPre-dose at day 1 to day 57 → SAD: Pre-dose at day 1 to day 57. MAD: Pre-dose at day 1 to day 85
    • Time frameChange in fasting plasma glucose from baselineBaseline up to Day 57 → SAD: Baseline up to Day 57
    • Time frameChange in fasting insulin from baselineBaseline up to Day 57 → SAD: Baseline up to Day 57 MAD: Baseline up to Day 85
    • Time frameChange in C-peptide from baselineBaseline up to Day 57 → SAD: Baseline up to Day 57 MAD: Baseline up to Day 85
    • Time frameChange in glucagon from baselineBaseline up to Day 57 → SAD: Baseline up to Day 57
    • Time frameChange in body weight from baselineBaseline up to Day 57 → SAD: Baseline up to Day 57 MAD: Baseline up to Day 85
    • Time frameChange in waist circumference from baselineBaseline up to Day 57 → SAD: Baseline up to Day 57 MAD: Baseline up to Day 85
    • Time frameCorrected QT(QTc) intervalPre-dose at day 1 to day 8 → SAD: Pre-dose at day 1 to day 8 MAD: Pre-dose at day-1 to day 36
    Title A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07532655
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
Apr 10, 2026
Primary completion
Jan 30, 2027 (estimated)
Completion
May 9, 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion